https://efba.uk/blog/n-acetylcysteine-iv-therapy/ 2026-11-09 monthly 0.7 https://efba.uk/assets/img/blog/n-acetylcysteine-iv-therapy-cover.webp N-acetylcysteine in IV therapy — the one antioxidant precursor with an approved intravenous product: what the FDA-approved Acetadote label and the UK Summaries of Product Characteristics state as a dose and indication (300 mg/kg over 20–21 hours to prevent hepatic injury after paracetamol overdose), the arithmetic between that licensed course and a 600 mg wellness bag, why the oral route reduces the N,N-diacetylcystine dimer back to cysteine while the intravenous route cannot, what PRESERVE and the COVID-19 meta-analysis found, why two randomised GlyNAC trials reached opposite conclusions, why the infusion reaction is a dose-rate problem rather than an allergy, and what a certificate of analysis must separate before a clinic orders https://efba.uk/blog/thiamine-iv-therapy/ 2026-11-06 monthly 0.7 https://efba.uk/assets/img/blog/thiamine-iv-therapy-cover.webp Thiamine in IV therapy — the one B vitamin with a genuine intravenous emergency: what the FDA-approved and UK licensed labels state as a dose and indication (100 mg IV then 50–100 mg daily versus 500–750 mg every eight hours), why the 100 mg thiamine figure in the traditional banana bag was never selected from a clinical trial, what VICTAS and the septic shock pilot found, the Wernicke encephalopathy signal reported with GLP-1 receptor agonists, the bisulfite incompatibility that destroys thiamine in solution, and why the approved label and the prospective safety data disagree about intradermal test dosing https://efba.uk/blog/zinc-selenium-iv-therapy/ 2026-10-26 monthly 0.7 https://efba.uk/assets/img/blog/zinc-selenium-iv-therapy-cover.webp Zinc and selenium in IV therapy — the two intravenous trace elements that carry an upper limit: what the licensed FDA labels state as an adult dose (3 mg/day zinc, 60 mcg/day selenium) and the parenteral-nutrition-only indication they cover, why every adequately powered randomised trial of supraphysiological selenium has been negative, how the European selenium ceiling of 255 µg/day was derived from a trial that found no benefit, the labelled copper-deficiency warning on intravenous zinc, and why plasma zinc and total selenium both mislead as status markers https://efba.uk/blog/iv-therapy-cold-chain-storage/ 2026-10-19 monthly 0.7 https://efba.uk/assets/img/blog/iv-therapy-cold-chain-storage-cover.webp IV product cold chain and storage — what an expiry date certifies and what it does not: the climatic zone a shelf life is measured against, why a Zone II stability dossier may not support a Zone IV market, the published evidence that the primary container outranks the refrigerator for oxidation-sensitive actives, why cold-side excursions are as common as heat, the 2019 regulatory action on light protection and its limits, and the two clocks that start when a bag is made up https://efba.uk/blog/iv-therapy-clinic-requirements/ 2026-10-12 monthly 0.7 https://efba.uk/assets/img/blog/iv-therapy-clinic-requirements-cover.webp IV therapy clinic requirements — the four compliance layers behind an intravenous service: the CQC position that IV vitamins for wellbeing are a regulated activity, the medicines-supply rules governing where stock may lawfully come from, the GMP and batch-certificate record a parenteral product must carry, the transfer of UAE pharmaceutical services to the Emirates Drug Establishment on 29 December 2025, and the advertising prohibitions that catch established clinics https://efba.uk/blog/iron-infusion-iv-therapy/ 2026-10-05 monthly 0.7 https://efba.uk/assets/img/blog/iron-infusion-iv-therapy-cover.webp Iron infusion and IV iron therapy — why the intravenous route genuinely out-delivers oral iron, how hepcidin makes daily tablets self-defeating, what the UK licence actually authorises, what the FDA boxed warning of 1 September 2026 and the EMA Article 31 referral of 3 September 2026 changed, why hypophosphataemia is formulation-specific, and the evidence graded by outcome https://efba.uk/blog/exosome-therapy/ 2026-09-28 monthly 0.7 https://efba.uk/assets/img/blog/exosome-therapy-cover.webp Exosome therapy — why no regulator anywhere has approved an exosome product, why MISEV2023 discourages the term unless endosomal origin is demonstrated, what happened to the microRNA courier model when it was tested quantitatively, why particle counts are not a potency assay, and the evidence graded by indication, route and regulatory status https://efba.uk/blog/vitamin-d-injection-iv-therapy/ 2026-09-20 monthly 0.7 https://efba.uk/assets/img/blog/vitamin-d-injection-iv-therapy-cover.webp Vitamin D injection and IV therapy — why no cholecalciferol product is authorised for intravenous administration, what the only UK-licensed vitamin D injection is actually licensed for, how an intramuscular depot behaves against daily oral dosing, why the randomised harm signals cluster around intermittent megadoses, and the evidence graded by outcome, schedule and route https://efba.uk/blog/peptide-therapy/ 2026-09-14 monthly 0.7 https://efba.uk/assets/img/blog/peptide-therapy-cover.webp Peptide therapy — what the FDA Pharmacy Compounding Advisory Committee voted on in July 2026, why the agency's own reviewers objected on chemical identity rather than efficacy, what the published BPC-157 evidence consists of, how TB-500 differs from thymosin beta-4, and the evidence graded by peptide and regulatory status https://efba.uk/blog/sleep-stress-iv-therapy/ 2026-09-06 monthly 0.7 https://efba.uk/assets/img/blog/sleep-stress-iv-therapy-cover.webp Sleep and stress IV therapy — why brain tryptophan entry is governed by the tryptophan to large-neutral-amino-acid ratio rather than the dose, what the 1991 and 1992 human infusion studies measured, what the glycine and magnesium sleep trials found and by which route, and the evidence graded by ingredient and route https://efba.uk/blog/collagen-iv-therapy/ 2026-08-30 monthly 0.7 https://efba.uk/assets/img/blog/collagen-iv-therapy-cover.webp Collagen IV therapy — why a 300 kDa triple helix cannot be infused, what a collagen drip actually contains, what the oral peptide meta-analyses found once funding source was separated out, and the evidence graded by indication and route https://efba.uk/blog/biotin-iv-therapy/ 2026-08-23 monthly 0.7 https://efba.uk/assets/img/blog/biotin-iv-therapy-cover.webp Biotin IV therapy — the carboxylase reactions biotin serves, the oral versus intravenous bioavailability data, what the hair and nail trials found, and the immunoassay interference the FDA has warned about https://efba.uk/blog/l-carnitine-iv-therapy/ 2026-08-16 monthly 0.7 https://efba.uk/assets/img/blog/l-carnitine-iv-therapy-cover.webp L-carnitine IV therapy — the carnitine shuttle, the muscle uptake ceiling, the two licensed deficiency indications, and evidence graded by indication https://efba.uk/ 2026-05-18 weekly 1.0 https://efba.uk/knowledge-bank/ 2026-05-18 weekly 0.8 https://efba.uk/catalogue/ 2026-06-17 monthly 0.9 https://efba.uk/assets/img/products/ivixir-to-infinity-md.webp IVIXIR To Infinity MD — NAD+, carnosine, vitamin C and riboflavin-5-phosphate formulation https://efba.uk/assets/img/products/ivixir-nad-300-md.webp IVIXIR NAD+ 300 MD — NAD+ formulation, 8 ml presentation https://efba.uk/assets/img/products/ivixir-myersence-md.webp IVIXIR MyerSence MD — Myers' Cocktail composition, 50 ml presentation https://efba.uk/blog/ 2026-08-09 weekly 0.7 https://efba.uk/blog/magnesium-iv-therapy/ 2026-08-09 monthly 0.7 https://efba.uk/assets/img/blog/magnesium-iv-therapy-cover.webp Magnesium IV therapy — eclampsia and torsades indications, the asthma evidence split, and dosing and hypermagnesaemia limits https://efba.uk/blog/amino-acid-iv-therapy/ 2026-08-03 monthly 0.7 https://efba.uk/assets/img/blog/amino-acid-iv-therapy-cover.webp Amino acid IV therapy — glutamine critical-care harm signal, PROTECTION kidney-protection trial, and evidence-graded dosing by molecule https://efba.uk/blog/b12-folate-methylation-iv-therapy/ 2026-07-27 monthly 0.7 https://efba.uk/assets/img/blog/b12-folate-methylation-iv-therapy-cover.webp Vitamin B12 and folate IV therapy — methylation cycle, route of administration, homocysteine outcome trials and evidence-graded dosing https://efba.uk/blog/alpha-lipoic-acid-iv-therapy/ 2026-07-19 monthly 0.7 https://efba.uk/assets/img/blog/alpha-lipoic-acid-iv-therapy-cover.webp Alpha-lipoic acid IV therapy — mechanism, decades of diabetic neuropathy trial evidence and dosing for intravenous ALA infusion https://efba.uk/blog/nad-iv-therapy/ 2026-07-12 monthly 0.7 https://efba.uk/assets/img/blog/nad-iv-therapy-cover.webp NAD+ IV therapy — mechanism, the 2024 head-to-head trial and dosing for intravenous NAD+ infusion https://efba.uk/blog/vitamin-c-iv-therapy/ 2026-07-05 monthly 0.7 https://efba.uk/assets/img/blog/vitamin-c-iv-therapy-cover.webp High-dose IV vitamin C — mechanism, clinical evidence and dosing for ascorbate infusion https://efba.uk/blog/glutathione-iv-therapy/ 2026-06-29 monthly 0.7 https://efba.uk/assets/img/blog/glutathione-iv-therapy-cover.webp Glutathione IV therapy — mechanism, clinical evidence and dosing for the body's master antioxidant https://efba.uk/blog/myers-cocktail-iv-therapy/ 2026-06-22 monthly 0.7 https://efba.uk/assets/img/blog/myers-cocktail-iv-therapy-cover.webp Myers' cocktail — ingredients, doses and evidence for IV micronutrient therapy https://efba.uk/blog/nad-vs-nmn-longevity/ 2026-06-18 monthly 0.6 https://efba.uk/assets/img/blog/nad-vs-nmn-longevity-cover.webp NAD+ vs NMN — an evidence-based comparison for longevity practice https://efba.uk/legal/privacy-policy.html 2026-05-13 monthly 0.4 https://efba.uk/legal/terms.html 2026-05-13 monthly 0.4 https://efba.uk/legal/legal-notice.html 2026-05-13 monthly 0.3 https://efba.uk/iv-drip-protocols/ 2026-09-14 monthly 0.9 https://efba.uk/request-quote/ 2026-09-16 monthly 0.9 https://efba.uk/distributors/ 2026-10-06 monthly 0.8 https://efba.uk/iv-vitamin-manufacturer/ 2026-10-26 monthly 0.9 https://efba.uk/iv-vitamin-export/ 2026-10-14 monthly 0.9 https://efba.uk/nad-iv-supplier/ 2026-10-26 monthly 0.8 https://efba.uk/iv-vitamin-supplier/ 2026-11-09 monthly 0.8